ClinicalTrials.gg
CompletedNCT01583530Updated Aug 7, 2013Results posted

Study of Belimumab Administered Subcutaneously to Healthy Subjects

A Phase 1 interventional study of Single Dose Group: Belimumab IV 240 mg and Single Dose Group: Belimumab SC 2 x 120 mg in Healthy, sponsored by Human Genome Sciences Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-07.

Sponsored by Human Genome Sciences Inc. (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
16th of 36
118 · median 81
Started
2011
with 2 others
Phase 1
7 of 36
none open now
Registered
12th of 36
by date
Lead sponsor
6 of 36
Human Genome Sciences Inc.

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 16th largest by enrollment, is one of 3 that started in 2011, is one of 7 in phase 1, and was the 12th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

The purpose of this study is to measure the amount of belimumab in the blood when given as an injection under the skin (subcutaneously; SC) and to evaluate the safety and tolerability of multiple injections under the skin in healthy subjects.

Read the detailed description

This study is designed to evaluate the absolute bioavailability, pharmacokinetics, tolerability, and safety of a single dose (groups 1-4) or multiple doses (groups 5-6) of belimumab administered subcutaneously (SC) to healthy subjects.

03

Conditions studied

  • Healthy

Keywords

  • Belimumab
  • Injections, Subcutaneous
  • Drug Administration Routes
  • Injections
  • Lupus Erythematosus, Systemic
  • Lupus
  • SLE
  • Systemic Lupus Erythematosus
  • Antibodies
  • Autoimmune Disease
  • Biological Therapy
  • Immune System Diseases
  • Pharmacokinetics
  • Biological Availability
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy subjects defined as no abnormalities identified by a detailed medical history, full physical exam, 12-lead (ECG), and clinical laboratory tests.
  • Body weight between 45 to 120 kg (99 to 264 lbs).
  • Must agree to use effective throughout the study and for 14 weeks after administration of belimumab.
  • Have the ability to understand the requirements of the study, provide written , and comply with the study protocol procedures.

Key Exclusion Criteria:

  • Pregnant or nursing.
  • Test positive for drugs or alcohol or have had a drug or alcohol dependence within the past year.
  • Have used any prescription medicines within the past 30 days or herbal/botanical supplements within the past 7 days or anticipate use during the study. May use prescription contraceptives, hormone replacement therapy, and over-the-counter medicines such as antihistamines or nutritional support such as vitamins, minerals, or amino acids.
  • Have received a within the past 30 days or anticipate receipt of a live vaccine during the study and within 4 months after last injection of belimumab.
  • Have a history of an allergic or anaphylactic reaction to drugs, food, or insect bite or sting requiring medical intervention.
  • Have a history of allergic reaction to contrast agents or biological medicines.
  • Have participated in a clinical trial and received an experimental medicine within the past 60 days.
  • Have received treatment with a B cell targeted therapy at any time.
  • Have required management of an infection within the past 14 days.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
118 participants (actual)

Study arms

  • Active comparator
    Belimumab IV 240 mg

    Biological: Single Dose Group: Belimumab IV 240 mg

  • Experimental
    Belimumab SC 2 x 120 mg

    Biological: Single Dose Group: Belimumab SC 2 x 120 mg

  • Experimental
    Belimumab SC 1 x 240 mg

    Biological: Single Dose Group: Belimumab SC 1 x 240 mg

  • Experimental
    Belimumab SC 1 x 200 mg

    Biological: Single Dose Group: Belimumab SC 1 x 200 mg

  • Experimental
    Belimumab SC 2 x 120 mg weekly

    Biological: Multiple Dose Group: Belimumab SC 2 x 120 mg weekly

  • Experimental
    Belimumab SC 1 x 200 mg weekly

    Biological: Multiple Dose Group: Belimumab SC 1 x 200 mg weekly

Interventions

06

What researchers measure

Primary outcomes

  1. Time to Reach Maximum Serum Drug Concentration (Tmax) Following a Single Dose of Belimumab Given as Intravenous Infusion (IV) or Subcutaneous Injection (SC)

    Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 42, 56, and 70

  2. Maximum Serum Drug Concentration (Cmax) Following a Single Dose of Belimumab Given as IV or SC

    Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 42, 56, and 70

  3. Area Under the Serum Drug Concentration-time Curve From Time 0 to Infinite Time (AUC0-∞) Following a Single Dose of Belimumab Given as IV or SC

    AUC (0-∞) = Area under the serum drug concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-last) plus C (last)/λz. C (last) is the last measurable concentration. λz was determined by linear regression (r2 ≥ 0.8) with uniform weighting of all data in the terminal linear portion of the log-transformed drug concentration-time profile.

    Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 42, 56, and 70

  4. Terminal Elimination Half-life (t1/2,Term) Following a Single Dose of Belimumab Given as IV or SC

    Terminal elimination half-life is the time measured for the serum drug concentration of belimumab to decrease by one half.

    Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 42, 56, and 70

  5. Absolute Bioavailability of a Single Dose of Belimumab Given as IV or SC

    Bioavailability (F) is a measurement of the rate and extent to which a drug reaches the systemic circulation. The bioavailability of belimumab administered by IV is compared to the bioavailability of belimumab administered via single-SC injection.

    Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 42, 56, and 70

Secondary outcomes

  1. Time to Reach Maximum Serum Drug Concentration (Tmax) Following Weekly (x 4) SC Injections of Belimumab

    Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 14, 21, 22, 23, 24, 25, 26, 27, 28, 31, 35, 42, 49, 63, 77, 91, and 119

  2. Maximum Serum Drug Concentration (Cmax) Following Weekly (x 4) SC Injections of Belimumab

    Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 14, 21, 22, 23, 24, 25, 26, 27, 28, 31, 35, 42, 49, 63, 77, 91, and 119

  3. Area Under the Serum Drug Concentration-time Curve From Time 0 to Infinite Time (AUC0-∞) Following Weekly (x 4) SC Injections of Belimumab

    AUC (0-∞) = Area under the serum drug concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-last) plus C (last)/λz. C (last) is the last measurable concentration. λz was determined by linear regression (r2 ≥ 0.8) with uniform weighting of all data in the terminal linear portion of the log-transformed drug concentration-time profile.

    Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 14, 21, 22, 23, 24, 25, 26, 27, 28, 31, 35, 42, 49, 63, 77, 91, and 119

  4. Terminal Elimination Half-life (t1/2,Term) Following Weekly (x 4) SC Injections of Belimumab

    Terminal elimination half-life is the time measured for the serum drug concentration of belimumab to decrease by one half.

    Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 14, 21, 22, 23, 24, 25, 26, 27, 28, 31, 35, 42, 49, 63, 77, 91, and 119

  5. Absolute Bioavailability of Weekly (x 4) SC Injections of Belimumab

    Bioavailability (F) is a measurement of the rate and extent to which a drug reaches the systemic circulation. The bioavailability following weekly (x 4) SC injections of belimumab was calculated by comparing the bioavailability of belimumab administered IV to the bioavailability of belimumab administered via 4 weekly SC injections.

    Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 14, 21, 22, 23, 24, 25, 26, 27, 28, 31, 35, 42, 49, 63, 77, 91, and 119

  6. Number of Participants Who Experienced Adverse Events

    Includes AEs reported in participants from the first dose of belimumab throughout the study through Day 70/Exit (single dose groups) or Day 119/Exit (multiple dose groups).

    Time frame: Up to Day 119

07

Results

Posted Aug 28, 2012

Participant flow

Participant flow — Overall Study
MilestoneBelimumab IV 240 mgBelimumab SC 2 x 120 mgBelimumab SC 1 x 240 mgBelimumab SC 1 x 200 mgBelimumab SC 2 x 120 mg WeeklyBelimumab SC 1 x 200 mg Weekly
Started192020192020
Completed191720181517
Not completed030153
Withdrew: Adverse event000001
Withdrew: Withdrawal by subject030112
Withdrew: Lost to follow-up000030
Withdrew: Lack of compliance000010

Outcome measures

PrimaryTime to Reach Maximum Serum Drug Concentration (Tmax) Following a Single Dose of Belimumab Given as Intravenous Infusion (IV) or Subcutaneous Injection (SC)
Time frame:
Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 42, 56, and 70
Reported as:
Median · days
Time to Reach Maximum Serum Drug Concentration (Tmax) Following a Single Dose of Belimumab Given as Intravenous Infusion (IV) or Subcutaneous Injection (SC)
daysBelimumab IV 240 mgBelimumab SC 2 x 120 mgBelimumab SC 1 x 240 mgBelimumab SC 1 x 200 mg
Time to Reach Maximum Serum Drug Concentration (Tmax) Following a Single Dose of Belimumab Given as Intravenous Infusion (IV) or Subcutaneous Injection (SC)0.09 (0.05 to 0.30)3.9 (0.9 to 9.8)4.9 (2.9 to 13.9)5.9 (1.9 to 13.9)
SecondaryTime to Reach Maximum Serum Drug Concentration (Tmax) Following Weekly (x 4) SC Injections of Belimumab
Time frame:
Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 14, 21, 22, 23, 24, 25, 26, 27, 28, 31, 35, 42, 49, 63, 77, 91, and 119
Reported as:
Mean · days
Time to Reach Maximum Serum Drug Concentration (Tmax) Following Weekly (x 4) SC Injections of Belimumab
daysBelimumab SC 2 x 120 mg WeeklyBelimumab SC 1 x 200 mg Weekly
Time to Reach Maximum Serum Drug Concentration (Tmax) Following Weekly (x 4) SC Injections of Belimumab5.8 ± 1.55.5 ± 1.2
PrimaryMaximum Serum Drug Concentration (Cmax) Following a Single Dose of Belimumab Given as IV or SC
Time frame:
Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 42, 56, and 70
Reported as:
Geometric mean · µg/mL
Maximum Serum Drug Concentration (Cmax) Following a Single Dose of Belimumab Given as IV or SC
µg/mLBelimumab IV 240 mgBelimumab SC 2 x 120 mgBelimumab SC 1 x 240 mgBelimumab SC 1 x 200 mg
Maximum Serum Drug Concentration (Cmax) Following a Single Dose of Belimumab Given as IV or SC86.2 ± 20.032.7 ± 29.031.6 ± 27.924.3 ± 40.3
PrimaryArea Under the Serum Drug Concentration-time Curve From Time 0 to Infinite Time (AUC0-∞) Following a Single Dose of Belimumab Given as IV or SC

AUC (0-∞) = Area under the serum drug concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-last) plus C (last)/λz. C (last) is the last measurable concentration. λz was determined by linear regression (r2 ≥ 0.8) with uniform weighting of all data in the terminal linear portion of the log-transformed drug concentration-time profile.

Time frame:
Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 42, 56, and 70
Reported as:
Geometric mean · µg∙day/mL
Area Under the Serum Drug Concentration-time Curve From Time 0 to Infinite Time (AUC0-∞) Following a Single Dose of Belimumab Given as IV or SC
µg∙day/mLBelimumab IV 240 mgBelimumab SC 2 x 120 mgBelimumab SC 1 x 240 mgBelimumab SC 1 x 200 mg
Area Under the Serum Drug Concentration-time Curve From Time 0 to Infinite Time (AUC0-∞) Following a Single Dose of Belimumab Given as IV or SC1030 ± 32.1788 ± 36.1812 ± 36.2612 ± 37.9
PrimaryTerminal Elimination Half-life (t1/2,Term) Following a Single Dose of Belimumab Given as IV or SC

Terminal elimination half-life is the time measured for the serum drug concentration of belimumab to decrease by one half.

Time frame:
Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 42, 56, and 70
Reported as:
Mean · days
Terminal Elimination Half-life (t1/2,Term) Following a Single Dose of Belimumab Given as IV or SC
daysBelimumab IV 240 mgBelimumab SC 2 x 120 mgBelimumab SC 1 x 240 mgBelimumab SC 1 x 200 mg
Terminal Elimination Half-life (t1/2,Term) Following a Single Dose of Belimumab Given as IV or SC18.2 ± 6.315.9 ± 5.318.2 ± 6.016.0 ± 5.1
PrimaryAbsolute Bioavailability of a Single Dose of Belimumab Given as IV or SC

Bioavailability (F) is a measurement of the rate and extent to which a drug reaches the systemic circulation. The bioavailability of belimumab administered by IV is compared to the bioavailability of belimumab administered via single-SC injection.

Time frame:
Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 42, 56, and 70
Reported as:
Mean · percentage bioavailability
Absolute Bioavailability of a Single Dose of Belimumab Given as IV or SC
percentage bioavailabilityBelimumab IV 240 mgBelimumab SC 2 x 120 mgBelimumab SC 1 x 240 mgBelimumab SC 1 x 200 mg
Absolute Bioavailability of a Single Dose of Belimumab Given as IV or SCNA (NA to NA)76.1 (64.5 to 89.9)81.8 (70.1 to 95.5)73.5 (59.7 to 90.5)
SecondaryMaximum Serum Drug Concentration (Cmax) Following Weekly (x 4) SC Injections of Belimumab
Time frame:
Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 14, 21, 22, 23, 24, 25, 26, 27, 28, 31, 35, 42, 49, 63, 77, 91, and 119
Reported as:
Geometric mean · µg/mL
Maximum Serum Drug Concentration (Cmax) Following Weekly (x 4) SC Injections of Belimumab
µg/mLBelimumab SC 2 x 120 mg WeeklyBelimumab SC x 1 200 mg Weekly
Maximum Serum Drug Concentration (Cmax) Following Weekly (x 4) SC Injections of Belimumab21.6 ± 23.219.5 ± 25.1
SecondaryArea Under the Serum Drug Concentration-time Curve From Time 0 to Infinite Time (AUC0-∞) Following Weekly (x 4) SC Injections of Belimumab

AUC (0-∞) = Area under the serum drug concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-last) plus C (last)/λz. C (last) is the last measurable concentration. λz was determined by linear regression (r2 ≥ 0.8) with uniform weighting of all data in the terminal linear portion of the log-transformed drug concentration-time profile.

Time frame:
Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 14, 21, 22, 23, 24, 25, 26, 27, 28, 31, 35, 42, 49, 63, 77, 91, and 119
Reported as:
Geometric mean · µg∙day/mL
Area Under the Serum Drug Concentration-time Curve From Time 0 to Infinite Time (AUC0-∞) Following Weekly (x 4) SC Injections of Belimumab
µg∙day/mLBelimumab SC 2 x 120 mg WeeklyBelimumab SC 1 x 200 mg Weekly
Area Under the Serum Drug Concentration-time Curve From Time 0 to Infinite Time (AUC0-∞) Following Weekly (x 4) SC Injections of Belimumab763 ± 29.8661 ± 31.2
SecondaryTerminal Elimination Half-life (t1/2,Term) Following Weekly (x 4) SC Injections of Belimumab

Terminal elimination half-life is the time measured for the serum drug concentration of belimumab to decrease by one half.

Time frame:
Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 14, 21, 22, 23, 24, 25, 26, 27, 28, 31, 35, 42, 49, 63, 77, 91, and 119
Reported as:
Mean · days
Terminal Elimination Half-life (t1/2,Term) Following Weekly (x 4) SC Injections of Belimumab
daysBelimumab SC 2 x 120 mg WeeklyBelimumab SC 1 x 200 mg Weekly
Terminal Elimination Half-life (t1/2,Term) Following Weekly (x 4) SC Injections of Belimumab20.3 ± 5.219.8 ± 4.9
SecondaryAbsolute Bioavailability of Weekly (x 4) SC Injections of Belimumab

Bioavailability (F) is a measurement of the rate and extent to which a drug reaches the systemic circulation. The bioavailability following weekly (x 4) SC injections of belimumab was calculated by comparing the bioavailability of belimumab administered IV to the bioavailability of belimumab administered via 4 weekly SC injections.

Time frame:
Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 14, 21, 22, 23, 24, 25, 26, 27, 28, 31, 35, 42, 49, 63, 77, 91, and 119
Reported as:
Mean · percentage bioavailability
Absolute Bioavailability of Weekly (x 4) SC Injections of Belimumab
percentage bioavailabilityBelimumab SC 2 x 120 mg WeeklyBelimumab SC 1 x 200 mg Weekly
Absolute Bioavailability of Weekly (x 4) SC Injections of Belimumab74.7 (62.6 to 89.1)77.9 (67.0 to 90.6)
SecondaryNumber of Participants Who Experienced Adverse Events

Includes AEs reported in participants from the first dose of belimumab throughout the study through Day 70/Exit (single dose groups) or Day 119/Exit (multiple dose groups).

Time frame:
Up to Day 119
Reported as:
Number · participants
Number of Participants Who Experienced Adverse Events
participantsBelimumab IV 240 mgBelimumab SC 2 x 120 mgBelimumab SC 1 x 240 mgBelimumab SC 1 x 200 mgBelimumab SC 2 x 120 mg WeeklyBelimumab SC 1 x 200 mg Weekly
At least 1 AE141116141819
At least 1 serious AE000011
An AE resulting in death000000

Adverse events

Collected over up to Day 119. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belimumab IV 240 mg—0/19 (0%)14/19 (73.7%)
Belimumab SC 2 x 120 mg—0/20 (0%)11/20 (55%)
Belimumab SC 1 x 240 mg—0/20 (0%)16/20 (80%)
Belimumab SC 1 x 200 mg—0/19 (0%)14/19 (73.7%)
Belimumab SC 2 x 120 mg Weekly—1/20 (5%)17/20 (85%)
Belimumab SC 1 x 200 mg Weekly—1/20 (5%)19/20 (95%)
Most frequent serious events
Most frequent serious events
EventBelimumab IV 240 mgBelimumab SC 2 x 120 mgBelimumab SC 1 x 240 mgBelimumab SC 1 x 200 mgBelimumab SC 2 x 120 mg WeeklyBelimumab SC 1 x 200 mg Weekly
AppendicitisInfections and infestations0/190/200/200/190/201/20
Pain in extremityMusculoskeletal and connective tissue disorders0/190/200/200/191/200/20
Most frequent other events
Showing 10 of 93
Most frequent other events
EventBelimumab IV 240 mgBelimumab SC 2 x 120 mgBelimumab SC 1 x 240 mgBelimumab SC 1 x 200 mgBelimumab SC 2 x 120 mg WeeklyBelimumab SC 1 x 200 mg Weekly
Injection site painGeneral disorders0/193/209/208/1914/2014/20
HeadacheNervous system disorders3/193/200/205/196/203/20
ErythemaSkin and subcutaneous tissue disorders1/190/200/200/190/204/20
Abdominal painGastrointestinal disorders3/190/200/200/190/200/20
Injection site haemorrhageGeneral disorders0/190/200/203/190/200/20
DiarrhoeaGastrointestinal disorders0/192/200/202/193/200/20
Injection site erythemaGeneral disorders0/191/203/201/191/203/20
Injection site haematomaGeneral disorders0/190/200/200/193/202/20
Injection site oedemaGeneral disorders0/190/203/200/190/200/20
Injection site swellingGeneral disorders0/190/200/200/191/203/20

Baseline characteristics

Age Continuous
Age Continuous(years)Belimumab IV 240 mgBelimumab SC 2 x 120 mgBelimumab SC 1 x 240 mgBelimumab SC 1 x 200 mgBelimumab SC 2 x 120 mg WeeklyBelimumab SC 1 x 200 mg WeeklyTotal
Mean37.3 ± 12.133.4 ± 11.435.2 ± 12.136.1 ± 9.433.7 ± 9.537.4 ± 9.735.5 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Belimumab IV 240 mgBelimumab SC 2 x 120 mgBelimumab SC 1 x 240 mgBelimumab SC 1 x 200 mgBelimumab SC 2 x 120 mg WeeklyBelimumab SC 1 x 200 mg WeeklyTotal
Female1213118111065
Male7791191053
Region of Enrollment
Region of Enrollment(participants)Belimumab IV 240 mgBelimumab SC 2 x 120 mgBelimumab SC 1 x 240 mgBelimumab SC 1 x 200 mgBelimumab SC 2 x 120 mg WeeklyBelimumab SC 1 x 200 mg WeeklyTotal
United States192020192020118
08

Study locations

4 sites
  • Daytona Beach, Florida, United States
  • Evansville, Indiana, United States
  • Dallas, Texas, United States
  • Madison, Wisconsin, United States
09

References and documents

Publications

  • Gupta SV, Fanget MC, MacLauchlin C, Clausen VA, Li J, Cloutier D, Shen L, Robbie GJ, Mogalian E. Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection. Drugs R D. 2021 Dec;21(4):455-465. doi: 10.1007/s40268-021-00369-w. Epub 2021 Nov 6. PubMed 34741731 ↗
  • Zhou X, Lee TI, Zhu M, Ma P. Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus. Drugs R D. 2021 Dec;21(4):407-417. doi: 10.1007/s40268-021-00363-2. Epub 2021 Oct 9. PubMed 34628605 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2012
First posted
Apr 24, 2012
Start
Feb 2011
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results first posted
Aug 28, 2012
Last update
Aug 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01583530
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 24, 2012
Start date
Feb 2011
Primary completion
Sep 2011
Completion
Sep 2011
Results posted
Aug 28, 2012
Last update
Aug 7, 2013

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion